Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma

Deshan F. Sebaratnam; Linda K. Martin; Supriya S. Venugopal; George Mangos; John Freiman; Paul de Souza; Annabelle Farnsworth; Karen Cheung; Richard A. Scolyer; Dédée F. Murrell

doi:10.1111/ijd.12614

Diffuse melanosis cutis in the setting of BRAF^V⁶⁰⁰^E metastatic melanoma

Deshan F. Sebaratnam, Linda K. Martin, Supriya S. Venugopal, George Mangos, John Freiman, Paul de Souza, Annabelle Farnsworth, Karen Cheung, Richard A. Scolyer, Dédée F. Murrell^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Case Report: A 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAF^V^600E mutation status, an unexpected finding given his age. He died two weeks after presentation. Discussion: As our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.

Original language	English
Pages (from-to)	1409-1411
Number of pages	3
Journal	International Journal of Dermatology
Volume	53
Issue number	11
DOIs	https://doi.org/10.1111/ijd.12614
Publication status	Published - 1 Nov 2014
Externally published	Yes

Access to Document

10.1111/ijd.12614

Cite this

@article{f02611d30bd94945a330cdfcf767481e,

title = "Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma",

abstract = "Case Report: A 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAFV600E mutation status, an unexpected finding given his age. He died two weeks after presentation. Discussion: As our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.",

author = "Sebaratnam, {Deshan F.} and Martin, {Linda K.} and Venugopal, {Supriya S.} and George Mangos and John Freiman and {de Souza}, Paul and Annabelle Farnsworth and Karen Cheung and Scolyer, {Richard A.} and Murrell, {D{\'e}d{\'e}e F.}",

year = "2014",

month = nov,

day = "1",

doi = "10.1111/ijd.12614",

language = "English",

volume = "53",

pages = "1409--1411",

journal = "International Journal of Dermatology",

issn = "0011-9059",

publisher = "Wiley-Blackwell, Wiley",

number = "11",

}

TY - JOUR

T1 - Diffuse melanosis cutis in the setting of BRAFV600E metastatic melanoma

AU - Sebaratnam, Deshan F.

AU - Martin, Linda K.

AU - Venugopal, Supriya S.

AU - Mangos, George

AU - Freiman, John

AU - de Souza, Paul

AU - Farnsworth, Annabelle

AU - Cheung, Karen

AU - Scolyer, Richard A.

AU - Murrell, Dédée F.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Case Report: A 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAFV600E mutation status, an unexpected finding given his age. He died two weeks after presentation. Discussion: As our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.

AB - Case Report: A 79-year-old Caucasian male presented with a 1-week history of diffuse progressive blue-gray discoloration of the skin subsequently found to due to diffuse melanosis cutis (DMC) in the setting of metastatic melanoma. Mutation testing demonstrated BRAFV600E mutation status, an unexpected finding given his age. He died two weeks after presentation. Discussion: As our understanding of the molecular subtypes of melanoma increases, in the future it may be possible to predict which melanoma patients have a predilection to developing DMC. Mutation testing of DMC patients should be considered as BRAF inhibitors, and other novel targeted therapies may improve the bleak prognosis associated with this unusual presentation of metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84911483974&partnerID=8YFLogxK

U2 - 10.1111/ijd.12614

DO - 10.1111/ijd.12614

M3 - Article

C2 - 25257244

AN - SCOPUS:84911483974

SN - 0011-9059

VL - 53

SP - 1409

EP - 1411

JO - International Journal of Dermatology

JF - International Journal of Dermatology

IS - 11

ER -

Diffuse melanosis cutis in the setting of BRAF^V⁶⁰⁰^E metastatic melanoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this